Publicaciones en las que colabora con Carlos Panizo Santos (70)

2024

  1. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

2023

  1. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

    Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100

  2. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

  2. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

2020

  1. Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

    British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073

2019

  1. Análisis de las alteraciones de la coagulación y fibrinolisis

    Principios de bioquímica clínica y patología molecular (Elsevier España), pp. 207-216

  2. Hemograma. Alteraciones eritrocitarias. Hemoglobinopatías

    Principios de bioquímica clínica y patología molecular (Elsevier España), pp. 105-119

  3. Metabolismo del hierro. Anemia ferropénica. Hemocromatosis

    Principios de bioquímica clínica y patología molecular (Elsevier España), pp. 121-130

  4. Síntesis y degradación dle hemo. Porfiria. Hiperbilirrubinemia

    Principios de bioquímica clínica y patología molecular (Elsevier España), pp. 131-141

  5. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma

    Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187

2018

  1. Post-transplant lymphoproliferative disease after liver transplantation

    Revista Espanola de Enfermedades Digestivas

  2. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

  3. Update on posttransplant lymphoproliferative disease

    Current Opinion in Nephrology and Hypertension, Vol. 27, Núm. 6, pp. 440-444

2017

  1. A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates

    Journal of Immunological Methods, Vol. 442, pp. 54-58

  2. Common variable immunodeficiency-associated granulomatous and lymphocytic interstitial lung disease successfully treated with a combination regimen of rituximab and azathioprine

    Medicina Clinica, Vol. 149, Núm. 7, pp. 312-313

  3. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study

    European Journal of Haematology, Vol. 98, Núm. 1, pp. 38-43

2016

  1. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity

    Immunologic Research, Vol. 64, Núm. 2, pp. 548-557

  2. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

    Nature Communications, Vol. 7